Medicina
Facultad
![Foto de Medicina](/img/uploaded/B3F8E74FDA254B3134B0031201D4E115.jpg)
![Foto de Iuliu Hațieganu University of Medicine and Pharmacy](/img/noimage_org.png)
Iuliu Hațieganu University of Medicine and Pharmacy
Cluj, RumaníaPublicaciones en colaboración con investigadores/as de Iuliu Hațieganu University of Medicine and Pharmacy (62)
2024
-
Clinician treatment choices for post-traumatic stress disorder: ambassadors survey of psychiatrists in 39 European countries
European Psychiatry, Vol. 67, Núm. 1
-
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97
-
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 2
-
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
Journal of Hepatology
-
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis
Hepatology, Vol. 79, Núm. 3, pp. 624-635
2023
-
Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode
Liver International, Vol. 43, Núm. 7, pp. 1548-1557
-
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products
Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553
-
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 204-222
-
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
-
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
European Journal of Cancer, Vol. 183, pp. 174-187
-
Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212
-
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Oncologist, Vol. 28, Núm. 1, pp. 59-71
-
Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding
Gut, Vol. 72, Núm. 4, pp. 749-758
-
Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome
Transplantation, Vol. 107, Núm. 6, pp. 1330-1340
-
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185
-
Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis
Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062
-
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
ESMO Open, Vol. 8, Núm. 6
-
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92
-
Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct
Pathology Research and Practice, Vol. 247
-
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069